Loading clinical trials...
Loading clinical trials...
To establish the maximum tolerated dose (MTD) of oral afatinib (BIBW2992) given in combination with gemcitabine or docetaxel in patients with relapsed or refractory tumors. To assess the safety of th...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT07287098 · Breast Neoplasms
NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms
NCT07258836 · Neoplasms, Healthy
NCT07169851 · Nausea, Vomiting, and more
NCT07628998 · Colorectal Neoplasms, Early Detection of Cancer
1200.93.33002 Boehringer Ingelheim Investigational Site
Dijon
1200.93.33001 Boehringer Ingelheim Investigational Site
Saint-Herblain
1200.93.33003 Boehringer Ingelheim Investigational Site
Toulouse
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions